Why the study?
Treatment effects of anticoagulants among patients with venous thromboembolism and cancer across different tumor types needed evaluation.
Do anticoagulant treatment effects on recurrent VTE and bleeding vary across different tumor types in patients with cancer-associated thrombosis?
Do anticoagulant treatment effects on recurrent VTE and bleeding vary across different tumor types in patients with cancer-associated thrombosis?
Anticoagulant treatment effects for VTE appear generally consistent across various common and high-risk tumor types, supporting current generalized treatment approaches in cancer-associated thrombosis.
Anticoagulant effects appear consistent across tumor types; leaves open tumor-specific differences needing prospective trials.
Aim: Treatment effects among anticoagulant-treated patients with venous thromboembolism (VTE) and cancer across tumor types were evaluated. Methods: Patients initiating an anticoagulant within 30 days after VTE were identified. After inverse probability treatment weighting, patients were stratified by tumor type. Interactions between treatment and tumor type on recurrent VTE, major bleeding and clinically relevant non-major bleeding were assessed using Cox proportional hazard models. Results: Treatment effects were generally not significantly different among patients with or without the following cancer types: prostate, breast, lung, pancreatic or multiple myeloma. Few significant interactions were observed for lung and pancreatic cancer. Conclusion: Anticoagulant treatment effects were generally consistent across tumor types. The significant interactions may indicate tumor-specific effects of anticoagulants, but further research is needed.
No takes yet. Share an insight, caveat, or question.
Cohen et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: